Adocia SA (EPA: ADOC)

Market Cap	89.68M
Revenue (ttm)	3.59M
Net Income (ttm)	-20.72M
Shares Out	15.46M
EPS (ttm)	-1.51
PE Ratio	n/a
Forward PE	2.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	370,816
Open	6.22
Previous Close	6.24
Day's Range	5.52 - 6.65
52-Week Range	5.11 - 12.66
Beta	0.80
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 17, 2025

About Adocia

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company’s clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and ra...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 78
• Stock Exchange: Euronext Paris
• Ticker Symbol: ADOC

Financial Performance

In 2023, Adocia's revenue was 6.05 million, a decrease of -65.16% compared to the previous year's 17.36 million. Losses were -21.16 million, 206.7% more than in 2022.